Coherus BioSciences Inc. (CHRS)

9.47
0.38 4.10
NASDAQ : Health Technology
Prev Close 9.10
Open 9.10
Day Low/High 9.10 / 9.60
52 Wk Low/High 8.05 / 26.55
Volume 146.55K
Avg Volume 596.60K
Exchange NASDAQ
Shares Outstanding 59.84M
Market Cap 571.47M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Even with Monday's sharp reversal, Jim Cramer says he still likes this market.

First Week of August 2018 Options Trading For Coherus BioSciences (CHRS)

Investors in Coherus BioSciences Inc saw new options begin trading this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Coherus BioSciences is Now Oversold (CHRS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of May 2018 Options Trading For Coherus BioSciences (CHRS)

Investors in Coherus BioSciences Inc saw new options become available this week, for the May 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Coherus BioSciences Provides Update On '619 IPR Institution Decision

Coherus BioSciences Provides Update On '619 IPR Institution Decision

Patent Trial and Appeal Board Denies Institution

Commit To Purchase Coherus BioSciences At $10, Earn 12.4% Annualized Using Options

Commit To Purchase Coherus BioSciences At $10, Earn 12.4% Annualized Using Options

Investors eyeing a purchase of Coherus BioSciences Inc stock, but cautious about paying the going market price of $13.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $10 strike, which has a bid at the time of this writing of 60 cents.

Coherus Secures Private Placement From Temasek

Coherus Secures Private Placement From Temasek

First tranche of $75 million secured

Coherus BioSciences Enters Oversold Territory (CHRS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Coherus BioSciences Stock Sees Short Interest Make 13.4% Move

Coherus BioSciences Stock Sees Short Interest Make 13.4% Move

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 708,208 share increase in total short interest for Coherus BioSciences Inc , to 6,000,299, an increase of 13.38% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Biotech Movers: Acceleron, Clovis, Coherus

Biotech Movers: Acceleron, Clovis, Coherus

Acceleron Pharma, Clovis Oncology and Coherus BioSciences premarket trading on Tuesday.

Notable Monday Option Activity: CHRS, BLUE, SAIC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Coherus BioSciences Inc , where a total volume of 3,847 contracts has been traded thus far today, a contract volume which is representative of approximately 384,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 47.2% of CHRS's average daily trading volume over the past month, of 814,875 shares.

Biotech Movers: Coherus, XBiotech, Flexion

Biotech Movers: Coherus, XBiotech, Flexion

Coherus BioSciences, XBiotech and Flexion Therapeutics were among the biotech stock movers in premarket trading on Monday.

Coherus BioSciences Receives Complete Response Letter From FDA For Its Biologics License Application For CHS-1701 (Pegfilgrastim Biosimilar Candidate)

Management to host a call today at 8:00 a.m. EDT to discuss FDA feedback

First Week of CHRS July 21st Options Trading

Investors in Coherus BioSciences Inc saw new options become available this week, for the July 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CHRS options chain for the new July 21st contracts and identified one put and one call contract of particular interest.

AbbVie Stock Lower on Humira Patent Ruling

AbbVie Stock Lower on Humira Patent Ruling

The drug is responsible for more than 60% of AbbVie's top line.

Coherus BioSciences Prevails In '135 IPR Decision

Patent Trial and Appeal Board Invalidates AbbVie U.S. Patent 8,889,135

First Week of June 16th Options Trading For Coherus BioSciences (CHRS)

Investors in Coherus BioSciences Inc saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CHRS options chain for the new June 16th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D- (Sell)